Stemedica Cell Technologies

CardioCell adds Stony Brook University to sites conducting phase IIa trial

Thursday, March 12, 2015

CardioCell, a Stemedica Cell Technologies subsidiary that designs allogeneic stem-cell therapies for cardiovascular indications, has expanded patient recruitment to Stony Brook University’s Heart Institute for its phase IIa clinical trial for chronic heart failure (HF). Recruitment for 20 qualified patients currently is underway at only Emory University in Atlanta, Northwestern University in Chicago, Stony Brook University on Long Island and the University of Pennsylvania in Philadelphia.

[Read More]

Stemedica to initiate study on Ischemic Stroke patients

Monday, March 7, 2011

Stemedica Cell Technologies, an adult allogeneic stem cell manufacturing, research and development company, has received IRB approval from the University of California, San Diego (UCSD) to initiate a phase I/II, multi-center, open-label clinical study to assess the safety, tolerability and preliminary efficacy of a single intravenous dose of allogeneic mesenchymal bone marrow cells to subjects with Ischemic Stroke.

[Read More]